Improved outcomes with oral tongue squamous cell carcinoma in Finland
Mroueh, Rayan; Haapaniemi, Aaro; Grénman, Reidar; Laranne, Jussi; Pukkila, Matti; Almangush, Alhadi; Salo, Tuula; Mäkitie, Antti (2017-05-08)
Mroueh, R., Haapaniemi, A., Grénman, R., Laranne, J., Pukkila, M., Almangush, A., Salo, T. and Mäkitie, A. (2017), Improved outcomes with oral tongue squamous cell carcinoma in Finland. Head Neck, 39: 1306–1312. doi:10.1002/hed.24744
© 2017 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Mroueh, R., Haapaniemi, A., Grénman, R., Laranne, J., Pukkila, M., Almangush, A., Salo, T. and Mäkitie, A. (2017), Improved outcomes with oral tongue squamous cell carcinoma in Finland. Head Neck, 39: 1306–1312. doi:10.1002/hed.24744, which has been published in final form at https://doi.org/10.1002/hed.24744. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2017120855517
Tiivistelmä
Abstract
Background: Incidence rates for oral tongue squamous cell carcinoma (SCC) are steadily rising worldwide.
Methods: All patients diagnosed with primary oral tongue SCC at the 5 university hospitals in Finland from 2005 to 2009 were studied. The mean follow-up time was 43 months (median, 54 months; range, 0–111 months).
Results: Three hundred sixty patients with primary oral tongue SCC were identified. Treatment with curative intent was provided for 328 patients (91%). The 5-year disease-specific survival (DSS) rates were as follows: stage I 87%; stage II 73%; stage III 69%; and stage IV 51%. The 5-year recurrence-free survival in general has improved from 47% in our previous published series (1995–1999) to 65% in the current series (p < .001).
Conclusions: The outcome of oral tongue SCC has significantly improved in Finland. However, the relatively high number of disease recurrences in patients with stage I and II disease, when compared with patients with stage III and IV disease, calls for an investigation of new treatment approaches.
Kokoelmat
- Avoin saatavuus [29929]